There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) ...

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports.

Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to InvestingPro data ...

ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) shares rose 12% following a recommendation from Cantor Fitzgerald to buy shares amid a possible leak of encouraging clinical trial data. Analyst Prakhar ...

Cantor Fitzgerald notes that the firm discovered “what appears” to be an “accidental release” of a snippet on the ASCO-GU daily news website ...

A U.S. Senate committee voted on Wednesday to advance President Donald Trump's nominee Howard Lutnick, billionaire chairman ...

Cantor Fitzgerald reiterated its confidence in ORIC Pharmaceuticals (NASDAQ:ORIC), maintaining an Overweight stock rating.

On Friday, Cantor Fitzgerald reaffirmed its Overweight rating on Cipher Mining shares (NASDAQ:CIFR), with a set price target of $11.00. The firm's analyst, Brett Knoblauch, provided insight into ...

Cantor Fitzgerald LP ’s lawsuit alleging a firm founded by four of its former investment bankers stole clients worth millions of dollars in profit was dismissed by a New York judge. Justice Nancy ...